GILD 50.50 -0.13 / Gilead Sciences, Inc. GILD 50.50 -0.13 / Gilead Sciences, Inc. | Benzinga

Monday, May 21, 2012

The Definitive Biotech ETF Guide (IBB, XBI, FBT) (ABT, AFFY, AMGN, AMLN, Analyst Color, BBH, CBST, CELG, FBT, GILD, IBB, INCY, Long Ideas, News, PBE, PFE, PJP, PSCH, QCOR, Sector ETFs, SLXP, VRTX, XBI, Short Ideas, Rumors, Small Cap Analysis, FDA, M&A, Events, Intraday Update, Markets, Analyst Ratings, Movers, Trading Ideas, ETFs / Mon, 01:35pm)

Wednesday, May 16, 2012

J.P. Morgan Reiterates Overweight Rating, $65 PT for Gilead Sciences (Analyst Color, GILD, Reiteration, Analyst Ratings / Wed, 12:12pm)

Tuesday, May 15, 2012

S&P Bullish On Biotech ETFs (FBT, IBB, XBI) (ABT, AFFY, AMGN, AMLN, Analyst Color, FBT, GILD, IBB, INCY, Long Ideas, MRK, News, PFE, PJP, Sector ETFs, VRTX, XBI, Short Ideas, Rumors, FDA, M&A, Intraday Update, Markets, Analyst Ratings, Trading Ideas, ETFs / Tue, 02:31pm)

Monday, May 14, 2012

HIV Drug Maker Gilead Sciences Scores Two Wins (GILD, Markets, Trading Ideas / Mon, 12:14pm)

Friday, May 11, 2012

UPDATE: FDA Advisory Committee Supports Approval of Gilead's Once-Daily Quad Single Tablet Regimen for HIV (GILD, News, FDA / Fri, 03:31pm)
From Earlier: FDA Advisory Committee Supports Approval of Gilead's Truvada® for Reducing the Risk of Acquiring HIV (GILD, News, FDA / Fri, 08:52am)

Thursday, April 19, 2012

Notable Options Activity in Gilead Sciences Inc (GILD, News, Options, FDA, Markets, Trading Ideas / Thu, 10:13am)
Benzinga's Top Pre-Market Gainers (EBAY, GILD, HGSI, MLNX, News, Pre-Market Outlook, Markets, Movers / Thu, 08:05am)
Financial Breakfast: Morning News Summary for April 19, 2012 (BAC, Bonds, CHK, CVI, DD, Earnings, EBAY, FFIV, GILD, GSK, HGSI, LUV, MS, News, PM, Futures, Guidance, Upgrades, Commodities, Downgrades, Forex, Technicals, FDA, M&A, Events, Global, Economics, Pre-Market Outlook, Markets, Analyst Ratings, Trading Ideas, General / Thu, 07:38am)
From Earlier: Gilead Announces Early Sustained Virologic Response Rates for GS-7977 Plus Ribavirin in Genotype 1 Treatment-Naïve Hepatitis C Patients (GILD, News, FDA / Thu, 07:22am)

Tuesday, April 03, 2012

Brean Murray Carret Discusses Gilead's Potential Competitor (Analyst Color, GILD, GSK, Reiteration, Analyst Ratings / Tue, 09:09am)

Thursday, March 15, 2012

UPDATE: Stifel Nicolaus Resumes Buy, $57 PT on Gilead Sciences (Analyst Color, GILD, Price Target, Initiation, Intraday Update, Analyst Ratings / Thu, 11:43am)

Tuesday, March 13, 2012

The Portfolio Bids Adieu to Gilead and Banco Itau (COP, GILD, ITUB, KSS, Markets / Tue, 04:01am)

Wednesday, March 07, 2012

Gilead's Quad Single Tablet Regimen for HIV Non-Inferior to Atripla in Pivotal Phase 3 Study (GILD, News, FDA / Wed, 04:01pm)
Morgan Stanley Updates Gilead Sciences Model (Analyst Color, GILD, Reiteration, Analyst Ratings / Wed, 10:26am)

Monday, February 27, 2012

Deutsche Bank Reiterates Buy, $57 PT on Gilead Sciences (Analyst Color, GILD, Price Target, Reiteration, Intraday Update, Analyst Ratings / Mon, 10:48am)
Morgan Stanley: 7977 Will Be Vital in All-Oral HCV Therapy (Analyst Color, GILD, Reiteration, Analyst Ratings / Mon, 10:06am)

Friday, February 24, 2012

UPDATE: Deutsche Bank Cuts Target to $57 on Gilead Sciences (Analyst Color, GILD, Price Target, Reiteration, Intraday Update, Analyst Ratings / Fri, 11:29am)

Thursday, February 23, 2012

JP Morgan Remains Bullish on Gilead Sciences (Analyst Color, GILD, Reiteration, Analyst Ratings / Thu, 11:30am)

Friday, February 17, 2012

Friday Slide: Opportunity Or Red Flag For Biotech ETFs? (GILD, IBB, XBI) (AAPL, AMGN, BBH, FBT, GILD, GOOG, IBB, LIFE, Long Ideas, News, QQQ, Sector ETFs, XBI, Short Ideas, Specialty ETFs, FDA, Intraday Update, Markets, Movers, Trading Ideas, ETFs / Fri, 04:10pm)
Gilead Falls On Disappointing Hep C Drug Data; Analysts Remain Bullish (ACHN, Analyst Color, BMY, C, GILD, IDIX, JPM, News, VRTX, Small Cap, FDA, Events, Intraday Update, Analyst Ratings, Movers / Fri, 01:30pm)
UPDATE: Analyst Mark Schoenebaum Discusses Gilead Sciences on CNBC (CNBC, GILD, Long Ideas, News, Short Ideas, FDA, Media, Trading Ideas / Fri, 11:29am)
Gilead Sciences Negative Data Ripples through Biotech Field, Boosting Vertex, Achillion; Knocking Idenix (ACHN, Analyst Color, GILD, IDIX, News, VRTX, FDA, Pre-Market Outlook, Analyst Ratings, Movers / Fri, 08:54am)
Deutsche Bank Sees Buying Opportunity on Gilead Share Weakess (Analyst Color, GILD, Reiteration, Pre-Market Outlook, Analyst Ratings / Fri, 08:41am)
Gilead Announces Data for Genotype 1 Null Responder Hepatitis C Patients Enrolled in ELECTRON Study; Viral Relapse Seen Post Treatment with GS-7977 Plus Ribavirin (GILD, News, FDA / Fri, 07:52am)

Tuesday, February 14, 2012

From Earlier: U.S. FDA Grants Priority Review for Truvada for Reducing the Risk of Acquiring HIV Infection (GILD, News, FDA / Tue, 10:10am)

Friday, February 10, 2012

Morgan Stanley Initiates Coverage on Gilead Sciences at Overweight, Announces PT of $65 (GILD, Price Target, Initiation, Analyst Ratings / Fri, 07:41am)

Friday, February 03, 2012

Gilead Sciences Soars On "Striking" Clinical Trial Data (Analyst Color, Earnings, GILD, JPM, Long Ideas, News, Guidance, Short Ideas, Price Target, FDA, Intraday Update, Markets, Analyst Ratings, Movers, Trading Ideas / Fri, 02:33pm)
Gilead Sciences Surging on Clinical Trial Data (GILD, Intraday Update, Movers / Fri, 11:50am)
UPDATE: JP Morgan Raises Target to $65 on Gilead Sciences (Analyst Color, GILD, Price Target, Reiteration, Intraday Update, Analyst Ratings / Fri, 10:36am)
Gilead Sciences up 10% Despite Lower Than Expected Q4 Profit (GILD, Pre-Market Outlook, Movers / Fri, 10:07am)
Brean Murray Maintains Sell on Idenix (GILD, IDIX, Reiteration, Pre-Market Outlook, Analyst Ratings / Fri, 10:02am)
UPDATE: Deutsche Bank Raises Target to $66 on Gilead Sciences (Analyst Color, GILD, Price Target, Reiteration, Pre-Market Outlook, Analyst Ratings / Fri, 08:13am)
JP Morgan Raises PT on Gilead Sciences to $65 (GILD, Price Target, Pre-Market Outlook, Analyst Ratings / Fri, 07:59am)

Thursday, January 26, 2012

Brean Murray Carret & Co. Raises Gilead Sciences PT To $60 (Analyst Color, GILD, Price Target, Analyst Ratings / Thu, 05:00pm)

Tuesday, January 24, 2012

Gilead Initiates Phase 2 Clinical Trial Evaluating GS-7340, A Low-Dose Novel Prodrug of Tenofovir for the Treatment of HIV (GILD, News, FDA / Tue, 05:06pm)